Diabetes in CKD
diabetes-in-ckd · society: KDIGO
Summary
KDIGO 2022 is a focused update of the 2020 guideline on diabetes management in CKD, with major revisions to Chapter 1 (comprehensive care) and Chapter 4 (glucose-lowering therapies in T2D); chapters on glycemic monitoring/targets, lifestyle, and care delivery remain unchanged. Key updates expand SGLT2i use down to eGFR ≥20 ml/min/1.73 m² and add a new recommendation for nonsteroidal MRA (finerenone) in T2D with albuminuria despite maximally tolerated RAS inhibition. The guideline emphasizes a layered comprehensive approach: lifestyle therapy plus first-line metformin + SGLT2i + RAS inhibitor + statin, with GLP-1 RA and ns-MRA added based on residual risk.
Current guideline: KDIGO 2022 Diabetes in CKD Guideline · 
download Anki sub-deck
Versions
- 2022 · KDIGO — KDIGO 2022 Diabetes in CKD Guideline